thelancet.com
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Among patients receiving maintenance dialysis, spironolactone 25 mg daily orally did
not reduce the composite outcome of cardiovascular mortality and hospitalisation due
to heart failure compared with...